Industries
Pharmaceutical Distribution
All research in Pharmaceutical Distribution — 4 reports.
38/100
Henry Schein Investment Research from a Long-Term Business Owner's Perspective
Henry Schein is a dental and medical consumables distribution platform with added specialty products and technology services. The core thesis is that the business is understandable and cash-generative, while its moat is moderate, GAAP operating margin is only about 5%, and the current price of $76.58 offers no obvious margin of safety. Rating Watch: a credible business that should be tracked, with a better entry point or clearer evidence of margin improvement needed before a conservative long-term investor should act.
42/100
Cencora Deep-Dive Value Investment Analysis
One of the three dominant U.S. pharmaceutical-distribution oligopolists, with FY2025 revenue of $321.3B. This is a low-margin, high-throughput, heavily regulated healthcare-infrastructure business whose strength is stable cash flow rather than fat margins. Rated Watch: the quality merits long-term tracking, but at roughly $270 the stock sits near the upper end of fair value with an ideal buy at 210-245 and no meaningful margin of safety.
44/100
McKesson: A Long-Term Owner's Perspective
A U.S. pharmaceutical distribution oligopoly with FY2026 revenue of $403.4 billion. The profit pool is migrating toward higher-quality businesses such as Oncology and RxTS, yet at the current price the margin of safety is thin and CVS accounts for 24% of revenue. Rating Watch: a high-quality business, but not a bargain at today's price.
41/100
Cardinal Health Deep Value Investment Analysis
A dominant U.S. pharmaceutical distribution oligopolist with cash flow that holds up well across the cycle, gaining extra credit for its pivot toward Specialty, MSO, and home care. But at $200.68, it trades at a trailing P/E of 31.9x and P/FCF of 25.6x — already in the middle of the $175-215 fair-value range, with an insufficient margin of safety.